Literature DB >> 32265209

Isolated cardiovascular involvement in light chain amyloidosis.

Ahamed Shaheer Ahmed1, Sampath Kumar1, Gautam Sharma2, Sudheer Arava3.   

Abstract

A 50-year-old woman presented with complaints of palpitations and breathlessness of 6 months' duration. She was being treated elsewhere as a case of dilated cardiomyopathy. On evaluation she had racoon eyes, poor progression of R wave on ECG and low-voltage complexes in the limb leads. Echocardiography revealed biventricular hypertrophy, diastolic dysfunction and moderate systolic dysfunction. Cardiac MRI showed features suggestive of amyloidosis. Bone marrow biopsy revealed raised plasma cell count, and endomyocardial biopsy showed amyloid deposits in the myocardium. Free lambda light chain levels were elevated, even though serum and urine electrophoresis did not show any monoclonal band. In this 'text book case of cardiac amyloidosis', apart from cardiovascular system no other organ system was affected, which is uncommon in primary light chain amyloidosis. The patient was started on CyBorD (cyclophosphamide, bortezomib and dexamethasone) regimen. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiovascular medicine; heart failure

Mesh:

Substances:

Year:  2020        PMID: 32265209      PMCID: PMC7244281          DOI: 10.1136/bcr-2019-233227

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

Review 1.  AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.

Authors:  Rodney H Falk; Kevin M Alexander; Ronglih Liao; Sharmila Dorbala
Journal:  J Am Coll Cardiol       Date:  2016-09-20       Impact factor: 24.094

2.  The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.

Authors:  S W Dubrey; K Cha; J Anderson; B Chamarthi; J Reisinger; M Skinner; R H Falk
Journal:  QJM       Date:  1998-02

Review 3.  Systemic amyloidosis.

Authors:  Ashutosh D Wechalekar; Julian D Gillmore; Philip N Hawkins
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

4.  Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.

Authors:  R A Kyle; A Linos; C M Beard; R P Linke; M A Gertz; W M O'Fallon; L T Kurland
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

5.  A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.

Authors:  Giovanni Palladini; Sajitha Sachchithanantham; Paolo Milani; Julian Gillmore; Andrea Foli; Helen Lachmann; Marco Basset; Philip Hawkins; Giampaolo Merlini; Ashutosh D Wechalekar
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

6.  Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.

Authors:  Claudio Rapezzi; Giampaolo Merlini; Candida C Quarta; Letizia Riva; Simone Longhi; Ornella Leone; Fabrizio Salvi; Paolo Ciliberti; Francesca Pastorelli; Elena Biagini; Fabio Coccolo; Robin M T Cooke; Letizia Bacchi-Reggiani; Diego Sangiorgi; Alessandra Ferlini; Michele Cavo; Elena Zamagni; Maria Luisa Fonte; Giovanni Palladini; Francesco Salinaro; Francesco Musca; Laura Obici; Angelo Branzi; Stefano Perlini
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

Review 7.  Cardiovascular magnetic resonance for amyloidosis.

Authors:  Marianna Fontana; Robin Chung; Philip N Hawkins; James C Moon
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

8.  Natural history and outcome in systemic AA amyloidosis.

Authors:  Helen J Lachmann; Hugh J B Goodman; Janet A Gilbertson; J Ruth Gallimore; Caroline A Sabin; Julian D Gillmore; Philip N Hawkins
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

9.  Systemic amyloidosis in England: an epidemiological study.

Authors:  Jennifer H Pinney; Colette J Smith; Jessi B Taube; Helen J Lachmann; Christopher P Venner; Simon D J Gibbs; Jason Dungu; Sanjay M Banypersad; Ashutosh D Wechalekar; Carol J Whelan; Philip N Hawkins; Julian D Gillmore
Journal:  Br J Haematol       Date:  2013-03-11       Impact factor: 6.998

  9 in total
  1 in total

1.  Marked recovery of cardiac function by chemotherapy and autologous stem cell transplantation of a patient with heart failure with preserved ejection fraction due to primary amyloid light-chain amyloidosis: a case report.

Authors:  Hidekazu Tanaka; Akihito Kitao; Hironobu Minami; Ken-Ichi Hirata
Journal:  Eur Heart J Case Rep       Date:  2022-01-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.